ES2115071T3 - Agente para la aplicacion por via transdermica, que contiene 3-ceto-desogestrel. - Google Patents

Agente para la aplicacion por via transdermica, que contiene 3-ceto-desogestrel.

Info

Publication number
ES2115071T3
ES2115071T3 ES93919108T ES93919108T ES2115071T3 ES 2115071 T3 ES2115071 T3 ES 2115071T3 ES 93919108 T ES93919108 T ES 93919108T ES 93919108 T ES93919108 T ES 93919108T ES 2115071 T3 ES2115071 T3 ES 2115071T3
Authority
ES
Spain
Prior art keywords
agent
transdermic
ceto
desogestrel
application via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93919108T
Other languages
English (en)
Inventor
Ralph Lipp
Clemens Gunther
Jutta Riedl
Ulrich Tauber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2115071T3 publication Critical patent/ES2115071T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBE UN AGENTE PARA APLICACION TRANSDERMAL, QUE ESTA CARACTERIZADO PORQUE CONTIENE 3 ALMENTE EN COMBINACION CON UNO O DOS ESTROGENOS.
ES93919108T 1992-08-21 1993-08-19 Agente para la aplicacion por via transdermica, que contiene 3-ceto-desogestrel. Expired - Lifetime ES2115071T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4227989A DE4227989A1 (de) 1992-08-21 1992-08-21 Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel

Publications (1)

Publication Number Publication Date
ES2115071T3 true ES2115071T3 (es) 1998-06-16

Family

ID=6466236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93919108T Expired - Lifetime ES2115071T3 (es) 1992-08-21 1993-08-19 Agente para la aplicacion por via transdermica, que contiene 3-ceto-desogestrel.

Country Status (13)

Country Link
EP (1) EP0655916B1 (es)
JP (1) JPH08500584A (es)
AT (1) ATE162945T1 (es)
AU (1) AU687013B2 (es)
CA (1) CA2141690A1 (es)
DE (2) DE4227989A1 (es)
DK (1) DK0655916T3 (es)
ES (1) ES2115071T3 (es)
FI (1) FI950774A0 (es)
GR (1) GR3026627T3 (es)
HU (1) HUT69406A (es)
NO (1) NO307325B1 (es)
WO (1) WO1994004157A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1135716A (zh) * 1993-12-27 1996-11-13 阿克佐诺贝尔公司 经皮吸收的药用制剂
AU5971294A (en) * 1994-01-27 1995-08-15 Schering Aktiengesellschaft Agent, intended for transdermal administration, containing 14alpha,17alpha-ethanoestra-1,3,5(10)-triene-3,17beta -diol
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
PL181582B1 (pl) * 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
WO1997003709A1 (de) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
KR100496109B1 (ko) * 1996-06-11 2005-09-09 아벤티스 파마 소시에떼아노님 개별격실에2종의활성성분을함유하는경피시스템,그의제조방법및의약으로서의그의용도
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
US6987101B1 (en) * 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
CA2315720A1 (en) 1997-12-22 1999-07-01 Bayer Corporation Inhibition of p38 kinase activity using substituted heterocyclic ureas
CA2319765A1 (en) * 1998-03-09 1999-09-16 Akzo Nobel Nv New contraceptive kit
AU5619399A (en) * 1998-08-11 2000-03-06 Akzo Nobel N.V. Progestogen-only contraceptive kit providing good cycle control
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
DK1380301T3 (da) 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP2305255B1 (en) 2001-12-03 2012-08-22 Bayer HealthCare LLC Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
WO2004054544A1 (fr) * 2002-12-10 2004-07-01 Besins International Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant un progestatif et un oestrogene, son procede de preparation et ses utilisations
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
JP2009501722A (ja) * 2005-07-15 2009-01-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ドロスピレノン含有経皮用薬剤供給装置及びその供給方法
RS52671B (sr) 2005-10-12 2013-06-28 Unimed Pharmaceuticals Llc Poboljšani gel testosterona i postupak korišćenja
WO2007053574A2 (en) 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Combinations comprising sorafenib and interferon for the treatment of cancer
US20080045589A1 (en) 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
TW200840595A (en) * 2006-12-12 2008-10-16 Organon Nv Oral contraceptive spray
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
AU2008275101B2 (en) * 2007-07-10 2014-08-21 Agile Therapeutics, Inc. Dermal delivery device with in situ seal
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
JP2013531067A (ja) 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
IE71202B1 (en) * 1990-12-17 1997-02-12 Akzo Nv Progestagen-only contraceptive
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen

Also Published As

Publication number Publication date
DK0655916T3 (da) 1998-09-23
NO950626L (no) 1995-02-20
EP0655916B1 (de) 1998-02-04
DE59308124D1 (de) 1998-03-12
CA2141690A1 (en) 1994-03-03
JPH08500584A (ja) 1996-01-23
EP0655916A1 (de) 1995-06-07
DE4227989A1 (de) 1994-06-09
AU687013B2 (en) 1998-02-19
ATE162945T1 (de) 1998-02-15
FI950774A7 (fi) 1995-02-20
NO950626D0 (no) 1995-02-20
FI950774L (fi) 1995-02-20
WO1994004157A1 (de) 1994-03-03
HU9500510D0 (en) 1995-04-28
HUT69406A (en) 1995-09-28
AU4950493A (en) 1994-03-15
NO307325B1 (no) 2000-03-20
GR3026627T3 (en) 1998-07-31
FI950774A0 (fi) 1995-02-20

Similar Documents

Publication Publication Date Title
ES2081823T3 (es) Agente para la aplicacion transdermica, que contiene gestoden.
ATE162945T1 (de) Mittel zur transdermalen applikation enthaltend 3-keto-desogestrel
ES2090715T3 (es) Disposicion que comprende un elemento de puerta y un cuerpo principal.
PT863773E (pt) Fralda tendo uma camada superior com uma locao que compreende um emoliente de poliester de poliol liquido e um agente imobilizante
BR9609967A (pt) Artigo absorvente descartável dotado de uma folha de topo com loção que contém um emoliente e um agente de imobilização de poliester de poliol
ATE78705T1 (de) Verbesserte metallhaltige pharmazeutika.
ES2110150T3 (es) Combinacion de productos desodorantes a base de acidos alcandicarboxilicos y lanocerinicos.
BR7802178A (pt) Agente de diagnostico para a deteccao de hidroperoxidos ou de substancias que reagem com a liberacao de hidroperoxidos ou de peroxidase ou de substancias ativas em peroxidado
PE7091A1 (es) Sistema de microcomputadora que incluye un circuito de restauracion de la microprocesadora
AR240339A1 (es) Procedimiento para explotar polvos y lodos que contienen cinc.
BR8603974A (pt) Aparelho para o fornecimento quantitativamente definido de um agente pressurizado,liquido ou espesso e arranjo
MX9100710A (es) Agentes fitoprotectores que contienen isoxazolinas o isotiazolinas asi como nuevas isoxazolinas e isotiazolinas
ES2022324B3 (es) Lubricantes que contienen agentes tensioactivos carboxilados, produccion y uso.
PT86138A (pt) Processo para a activacao transdermica ou topica utilizando um sistema terapeutico transdermico activado pelo utente
AU4538797A (en) Plasters containing active substances
DE68905344D1 (de) Bedienungsvorrichtung oder dgl.
PA8454301A1 (es) Composiciones solubilizadas de sertralina
DE69209335D1 (de) Mittel zur Zersetzung von Gallensteinen
ES2073731T3 (es) Medio para aplicacion transdermica que contiene rolipram.
MX9202278A (es) Agentes con actividad interfacial que contienen nitrogeno.
FR2663849B1 (fr) Composition cicatrisante a usage local.
ITBZ920042A1 (it) Dispositivo per l'applicazione di tratti di nastro o di bigliettini su pezzi da lavorare.
DK0653938T3 (da) Topisk middel
ES2054099T3 (es) Composicion estabilizada de interleucina-1-g(b).
BR9402699A (pt) Use de composto, compostos e medicamentos que abaixam o colesterol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 655916

Country of ref document: ES